News | Remote Monitoring | July 11, 2023

First U.S. Patients Implanted with Innovative FIRE1 Remote Heart Failure Monitoring System in Early Feasibility Study

FIRE1 announced the start of the first U.S. clinical study of its remote heart failure monitoring system, designed to provide unique insights to the care team and alert to deteriorating patient conditions for the almost 10M Americans with HF

FIRE1 announced the start of the first U.S. clinical study of its remote heart failure monitoring system, designed to provide unique insights to the care team and alert to deteriorating patient conditions for the almost 10M Americans with HF

July 11, 2023 — FIRE1 announced that the first U.S. patients have been successfully implanted with its FIRE1 System for remote heart failure monitoring in an Early Feasibility Study. The study will assess FIRE1’s novel solution to improve outcomes for heart failure patients. The first patient was implanted at Austin Heart, Texas, where Kunjan Bhatt, MD, leads the study as Principal Investigator and Thomas McMinn, MD, performed the implants.

“We are delighted to announce the first implants in the U.S. of this new, transformative technology for patients with chronic heart failure,” said Dr. Bhatt. “The procedures were very straightforward, and the patients tolerated the procedure well without any complications. We are excited to use the unique insights we will get from this device to improve patient care. On behalf of Austin Heart, the Heart Hospital of Austin, and St. David’s Healthcare, we are honored to launch research of this technology in the U.S.”

“This device may offer a completely new way of measuring chronic heart failure,” said Nir Uriel, MD, National Principal Investigator for the study and Director of Heart Failure, Heart Transplant and Mechanical Circulatory Support programs at New York-Presbyterian. “The data gathered outside of the U.S. has been promising, and we look forward to studying its use in the U.S.”

Dr. Uriel is also a Professor of Medicine in the Division of Cardiology at Columbia University Vagelos College of Physicians and Surgeons and an adjunct Professor of Medicine in the Greenburg Division of Cardiology at Weill Cornell Medicine.

FIRE1 CEO and President Conor Hanley said, “We have made great clinical progress in Europe and I am proud to announce the milestone of first cases in the U.S., the largest healthcare market in the world. I want to express my gratitude to all the patients who continue to put their faith in us and their care teams who are working tirelessly to bring this important technology to market. The FIRE1 team is committed to its mission of helping millions of patients living with heart failure to get their normal lives back, and today is an important step forward on this journey.”

For more information: www.fire1foundry.com


Related Content

News | Heart Failure

Oct. 22, 2025 – Ventric Health, a medtech innovator enabling early detection of heart failure (HF) in a primary care ...

Home October 28, 2025
Home
News | Heart Failure

Oct. 16, 2025 — Imbria Pharmaceuticals, has announced a partnership with the Hypertrophic Cardiomyopathy Association ...

Home October 16, 2025
Home
News | Heart Failure

Sept. 24, 2025 — The Family Heart Foundation, a leading research and advocacy organization, has announced the online ...

Home September 24, 2025
Home
News | Heart Failure

Sept. 22, 2025 — The latest findings on heart failure (HF) published by the Heart Failure Society of America (HFSA) ...

Home September 22, 2025
Home
News | Heart Failure

Sept. 11, 2025 — Newswise — A new Mayo Clinic study finds that many heart attacks in people under 65 — especially women ...

Home September 15, 2025
Home
News | Heart Failure

Aug. 14, 2025 — Analytics For Life, in collaboration with its U.S. commercial partner CorVista Health, announced they ...

Home August 15, 2025
Home
News | Heart Failure

Aug. 6, 2025 — Ventric Health, a medtech company enabling early detection of heart failure (HF) in a primary care ...

Home August 06, 2025
Home
News | Heart Failure

July 14, 2025 — Bayer has announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA (finerenone) to ...

Home July 14, 2025
Home
News | Heart Failure

June 23, 2025 — iRhythm Technologies, Inc. announced the results from two large-scale real-world studies presented at ...

Home June 25, 2025
Home
News | Heart Failure

June 3, 2025 — Bayer announced it will present multiple new analyses of the Kerendia (finerenone) clinical trial program ...

Home June 04, 2025
Home
Subscribe Now